GenSci098

GenSci098 is a humanized anti-TSHR (thyroid stimulating hormone receptor) antagonistic monoclonal antibody developed for the treatment of Thyroid Eye Disease (TED), also known as Graves' ophthalmopathy. TED is an autoimmune orbital inflammatory disease associated with thyroid dysfunction, particularly Graves' disease, and can lead to significant morbidity including vision impairment. GenSci098 acts by inhibiting TSHR, thereby blocking the pathological activation of orbital fibroblasts that drive inflammation and tissue remodeling in TED. Preclinical studies have demonstrated that GenSci098 binds strongly to TSHR and effectively blocks its activity, reducing pro-inflammatory cytokine production and thyroid hormone secretion without inducing hypothyroidism in animal models. The drug is currently in Phase 1 clinical trials for TED. It was developed by Changchun GeneScience Pharmaceutical Co., Ltd., which has received regulatory approval to commence clinical trials both from the US FDA and China's NMPA[1][2][3][4][5].

Other names

GenSci098 InjectionGenSci-098 InjectionGenSci 098 Injection